Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-08-20Clinical Trial Update: Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer [NA]
A completed study assessing the feasibility of using intratumoral washing fluid to detect EGFR mutations in non-small cell lung cancer.
-
CLINICAL_TRIALS research · 2025-08-20Clinical Trial Update: Real World Stage II-III NSCLC Patients Receiving Neoadjuvant Chemo-immunotherapy and no Surgical Resection
This clinical trial is recruiting real-world patients with non-small cell lung cancer to evaluate neoadjuvant chemo-immunotherapy in individ…
-
CLINICAL_TRIALS trial_result · 2025-08-19Clinical Trial Update: A Trial of AK104 Plus Anlotinib in NSCLC [Phase 1, Phase 2]
Clinical trial update indicating completion of Phase 1 and Phase 2 studies of AK104 plus anlotinib in non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2025-08-19Clinical Trial Update: A Study to Examine Biomarkers From Lung and Blood Samples in Participants With Suspected Lung Cancer
A completed study from Janssen examining biomarkers in lung and blood samples from participants with suspected non-small cell lung cancer.
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade [Phase 2]
Phase 2 clinical trial evaluating anti-PD-1/PD-L1 antibodies in combination with bevacizumab and metronomic cyclophosphamide in patients wit…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-08-19Clinical Trial Update: HS-IT101 Injection for Advanced NSCLC [Phase 1]
Phase 1 clinical trial update for HS-IT101 Injection in advanced non-small cell lung cancer, with the study listed as not yet recruiting.
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: Iparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC [Phase 2]
Phase 2 clinical trial evaluating iparomlimab and tuvonralimab in combination with 2 or 4 cycles of chemotherapy as neoadjuvant therapy for …
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer [Phase 1]
The document describes a Phase 1 clinical trial of aumolertinib in European participants with non-small cell lung cancer, currently recruiti…
-
CLINICAL_TRIALS trial_result · 2025-08-17Clinical Trial Update: Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer [Phase 3]
A Phase 3 trial evaluating pemetrexed/platinum with or without bevacizumab in patients with EGFR/ALK-negative non-squamous non-small cell lu…
-
CLINICAL_TRIALS trial_result · 2025-08-17Clinical Trial Update: Comparison of Longer-term (5 Year+) Outcomes (Survival) of Smokers, Ex-smokers, Never Smoker and Quitters
Clinical trial update reporting longer-term (5+ year) survival outcomes. It compares smokers, ex-smokers, never smokers, and quitters in pat…
-
CLINICAL_TRIALS other · 2025-08-17Clinical Trial Update: Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation [Phase 2]
A Phase 2 clinical trial update on combination therapies with adagrasib for advanced non-small cell lung cancer with KRAS G12C mutation; the…
-
CLINICAL_TRIALS research · 2025-08-17Clinical Trial Update: Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors [Phase 1]
Phase 1 clinical trial update on cabozantinib alone or with atezolizumab for locally advanced or metastatic solid tumors; the study lists mu…
-
CLINICAL_TRIALS trial_result · 2025-08-17Clinical Trial Update: Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) [Phase 3]
A Phase 3 trial MK-7339-012/KEYLYNK-012 evaluating pembrolizumab with concurrent chemoradiation followed by pembrolizumab with or without ol…
-
CLINICAL_TRIALS trial_result · 2025-08-17Clinical Trial Update: Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology [NA]
A completed clinical trial evaluating whether therapeutic patient education can reduce the toxicity associated with immune checkpoint inhibi…
-
CLINICAL_TRIALS research · 2025-08-17Clinical Trial Update: A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) [Phase 2]
This is an update announcing a Phase II clinical study evaluating HLX43 in adults with advanced non-small cell lung cancer, currently recrui…
-
CLINICAL_TRIALS research · 2025-08-17Clinical Trial Update: Combination Study of Guadecitabine/ASTX727 and Pembrolizumab [Phase 1]
A Phase 1 trial evaluating the safety of combining guadecitabine and ASTX727 with pembrolizumab in non-small cell lung cancer, currently rec…
-
CLINICAL_TRIALS trial_result · 2025-08-15Clinical Trial Update: Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies [Phase 1]
Phase 1 dose-escalation and expansion study of intratumoral mRNA-2752 in advanced malignancies has completed, with expansion cohorts in seve…
-
CLINICAL_TRIALS research · 2025-08-15Clinical Trial Update: A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors [Phase 2]
A Phase 2 study of IBI363 in combination therapy for advanced solid tumors, including EGFR-mutant non-small cell lung cancer and platinum-re…
-
CLINICAL_TRIALS research · 2025-08-15Clinical Trial Update: Resistance to the Tyrosine Kinase Inhibitor Osimertinib and Pharmacokinetics in Non-small Cell Lung Cancer
This clinical trial update investigates resistance to the EGFR inhibitor osimertinib and its pharmacokinetics in non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2025-08-15Clinical Trial Update: 1st Line Durvalumab in PS 2 NSCLC Patients [Phase 2]
Clinical trial update describing a Phase 2 study of first-line durvalumab in performance status 2 non-small cell lung cancer patients (stage…
-
FDA approval · 2025-08-14FDA Approved: LAZCLUZE — Supplemental Application (Janssen Biotech, Inc.)
FDA approved Janssen's supplemental NDA for Lazertinib (LAZCLUZE), expanding its use in non-small cell lung cancer.
-
FDA approval · 2025-08-14FDA Approved: RYBREVANT — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for Rybrevant (amivantamab-vmjw) from Janssen Biotech, Inc.
-
CLINICAL_TRIALS trial_result · 2025-08-14Clinical Trial Update: The Watch the Spot Trial [NA]
The Watch the Spot Trial (NCT02623712), sponsored by Kaiser Permanente, has completed its study on solitary pulmonary nodules and related co…
-
CLINICAL_TRIALS research · 2025-08-14Clinical Trial Update: Pan-tumor MRD Study
Paradigm Health's Pan-tumor MRD study (NCT06605404) is currently recruiting across several solid tumor indications including bladder, esopha…
-
CLINICAL_TRIALS trial_result · 2025-08-14Clinical Trial Update: Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors [Phase 1]
A Phase 1 trial evaluating tovorafenib (DAY101) alone or with pimasertib for melanoma and other solid tumors has been terminated.